

RILEXINE®
(cephalexin tablets)
Chewable Tablets

Antimicrobial for Oral Use in Dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: RILEXINE chewable tablets are a chewable, bisected tablet supplied in 3 sizes containing 150 mg, 300 mg, and 600 mg of cephalexin. Cephalexin is a cephalosporin, beta-lactam, broad spectrum antibiotic. The full chemical name for cephalexin is 7-(D-α-amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate.

INDICATION: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of *Staphylococcus pseudintermedius*.

DOSAGE AND ADMINISTRATION: The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days.

Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to cephalexin. Therapy with RILEXINE chewable tablets may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.

CONTRAINDICATIONS: RILEXINE chewable tablets are contraindicated in dogs with a known allergy to cephalexin or to the β-lactam (any of the penicillins or cephalosporins) group of antibiotics.

WARNINGS: For use in dogs only. Not for use in humans. Keep this drug out of the reach of children. Antimicrobials, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. Sensitized individuals handling such antimicrobials, including cephalexin, should avoid contact of the product with the skin and mucous membranes in order to minimize the risk of allergic reactions.

In case of ingestion by humans contact a physician immediately. Physicians may contact a poison control center for advice concerning cases of ingestion by humans.

PRECAUTIONS: Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.

RILEXINE chewable tablets are designed to taste good. **Store RILEXINE chewable tablets out of reach of dogs, cats, and other pets in a secured location.** Post approval experience has shown that dogs and cats may willingly consume more than the recommended dosage of RILEXINE chewable tablets, which can result in overdose. Adverse reactions may occur if large quantities of tablets are ingested (see **Adverse Reactions, Animal Safety, and Information for Dog Owners** sections). If the product is dispensed in a container other than the original, prescribers should consider adding a statement on the bottle label reminding the owner that RILEXINE chewable tablets are designed to taste good and should be stored out of reach of pets in a secured location.

The safe use of RILEXINE chewable tablets in dogs intended for breeding and in pregnant or lactating bitches has not been evaluated.

Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antimicrobials. Cephalosporin antimicrobials may also cause falsely elevated urine protein determinations. Some antimicrobials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.

Occasionally, cephalosporins have been associated with myelotoxicity, thereby creating a toxic neutropenia.¹ Other hematological reactions observed with cephalosporin therapy include neutropenia, anemia, hypoprothrombinemia, thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), platelet dysfunction, and transient increases in serum aminotransferases.²

ADVERSE REACTIONS: The most common adverse reactions in dogs include diarrhea, vomiting, anorexia and lethargy.

A total of 211 dogs were included in the field study safety analysis. Adverse reactions reported in dogs treated with RILEXINE chewable tablets and placebo are summarized in Table 1.

Table1: Number of Adverse Reactions* Reported During the Field Study with RILEXINE chewable tablets

ADVERSE REACTION	RILEXINE chewable tablets n = 145	Placebo n = 66
Number of dogs with adverse reactions [†]	50 (34%)	22 (33%)
	# of Each Event*	# of Each Event*
Vomiting	29	9
Diarrhea	19	6
Anorexia	13	2
Lethargy	9	3
Pruritus	5	0
Dermatitis	4	3
Skin Lesions	5	1
Otitis Externa	4	2
Polydipsia	2	2
Somnolence	2	0
Flatulence	1	1
Tachypnea	1	1

*Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

No clinically significant differences were observed in the mean values for all laboratory tests including urinalysis between RILEXINE chewable tablets and placebo-treated dogs. At the end of treatment, group means for neutrophils, WBC, and globulin values were significantly higher in the placebo group than in the RILEXINE chewable tablets group; whereas, group mean values for eosinophils, A/G Ratio values, and total protein values were significantly higher in the RILEXINE chewable tablets group than in the placebo group. For all six of these parameters, the differences were not clinically significant and the mean values for each of the parameters remained within the normal range.

To report suspected adverse drug events or for technical assistance contact Virbac AH, Inc. at 1-800-338-3659. Visit us.virbac.com for product details. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

INFORMATION FOR DOG OWNERS: Owners should be advised that RILEXINE chewable tablets are designed to taste good. Owners should be instructed to keep the product in a secured storage area out of the reach of pets in order to prevent accidental ingestion or overdose. Post approval experience has shown that dogs and cats may willingly consume more than the recommended dosage of RILEXINE chewable tablets. Adverse reactions may occur if large quantities of tablets are ingested (see **Precautions, Adverse Reactions, and Animal Safety** sections).

Owners should be advised to contact their veterinarian immediately if the dog ingests more tablets than prescribed or if other pets ingest RILEXINE chewable tablets. In the case of accidental ingestion by humans, contact a physician immediately.

CLINICAL PHARMACOLOGY: Cephalexin belongs to the cephalosporin family of bactericidal antibiotics.

Cephalexin is readily and almost completely absorbed following oral administration (90% absolute bioavailability). Blood concentrations are proportional to dose within the range of at least 15 to 45 mg/kg. Binding to canine plasma proteins is low, ranging from 9 to 13% for cephalexin concentrations of 0.5 to 100 µg/mL.

Food reduces the peak cephalexin concentrations but has negligible effect on the extent of absorption.

A summary of the pharmacokinetics (PK) observed in fed and fasted Beagle dogs administered a single 22 mg/kg dose is provided in Table 2.

Table 2: Pharmacokinetics Parameter values (mean ± standard deviation), protein-corrected in fasted and fed dogs following a single administration of 22 mg/kg dose of RILEXINE chewable tablets (N = 12)

Parameter	FASTED Mean ± SD ¹	FED Mean ± SD ¹
AUCINF_obs (mg·h/L)	105.36 ± 17.31	108.35 ± 25.85
AUClast (mg·h/L)	97.33 ± 13.18	95.19 ± 11.84
Cmax (mg/L)	21.66 ± 2.74	16.99 ± 2.71
T _{1/2} (h)	7.33 ± 4.30	8.79 ± 6.44
Tmax (h)	1.42 ± 0.42	1.17 ± 0.25

¹SD = Standard Deviation

Cephalosporins are associated with time dependent killing effects. Accordingly, the pharmacodynamic (PD) target is time above MIC (T>MIC). For staphylococcal infections, the goal for time above MIC is 40% of the dosing interval (which translates to 4.8 hrs for a BID dosing schedule). For streptococcal infections, the target for time above MIC is 60% of the dosing interval (i.e., 7.2 hrs). To assess whether or not the PK-PD target is met with a 22mg/kg BID dosing regimen under fed and fasted conditions, it was assumed that the MIC₅₀ for *S.pseudintermedius* is 2µg/mL. Plasma drug concentrations were normalized to exactly 22mg/kg dose and corrected for 10% protein binding (protein binding observed in canine plasma).

Under fasted conditions, all targets were met in all dogs after the first daily dose. With food, the target for *S. aureus* was met by the second daily dose. Therefore, a 22 mg/kg BID dosing interval under fed or fasted conditions succeeded in attaining the PK-PD targets.

MICROBIOLOGY: Cephalexin is a cephalosporin antibiotic. Like other β-lactam antimicrobials, cephalexin exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalent binding to the penicillin-binding proteins (PBPs) (i.e., transpeptidase and carboxypeptidase), which are essential for synthesis of the bacterial wall. Minimum Inhibitory Concentrations (MICs) for cephalexin against label-claim pathogens isolated from canine pyoderma in a 2008-2009 U.S. field trial are presented in Table 3. All MICs were determined in accordance with the Clinical Laboratory Standards Institute (CLSI) standards.

Table 3: Summary of Cephalexin MIC values against *S. pseudintermedius* isolates from 88 dogs treated with RILEXINE® (cephalexin tablets) Chewable Tablets for bacterial pyoderma in a U.S. field study during 2008-2009

Microbial Treatment Outcome	Time of Sampling	MIC ₅₀ µg/mL	MIC ₉₀ µg/mL	MIC Range µg/mL
Success (n = 61) *	Pre-treatment	1	2	1-2
Failure (n = 27) **	Pre-treatment	1	2	1-8
	Post-treatment (n = 17)	2	16	1-32

*No post-treatment sampling was conducted due to the absence of lesions.

**Of the 27 failures, 10 did not have positive post-treatment cultures.

EFFECTIVENESS: The clinical effectiveness of RILEXINE chewable tablets was established in a randomized, multi-location, placebo-controlled field study (see Table 4). In this study, 131 dogs with secondary superficial bacterial pyoderma treated with either RILEXINE chewable tablets (n=91) at 22 mg/kg (10 mg/lb) body weight or with a negative control (n = 40), twice daily for 28 days, were analyzed. RILEXINE chewable tablets were considered superior to the placebo (70% success rate vs. 13% respectively) in the treatment of secondary superficial bacterial pyoderma caused by susceptible strains of *S.pseudintermedius*.

Table 4: Primary endpoint: Percentage of Cure* in the Effectiveness population

Treatment	RILEXINE chewable tablets	Placebo	p-value
N	91	40	
Success	64 (70.3%)	5 (12.5%)	0.0009
Failures	27	35	

*Absence of lesions at the end of the study.

PALATABILITY: The palatability of RILEXINE chewable tablets was evaluated in two separate multi-location studies. In the first study, 39 client-owned dogs were dosed with RILEXINE chewable tablets at 22mg/kg and evaluated for palatability of the product. Palatability testing was performed twice daily prior to feeding for 7 days. Dogs freely consumed (from empty bowl or open hand) 80.8% of their doses. In a second study, 64 client-owned dogs enrolled in the field efficacy study were evaluated in a similar manner and freely consumed 78.4% of their doses.

ANIMAL SAFETY: RILEXINE chewable tablets were administered orally three times a day to 12-week-old healthy Beagles at 0mg/kg (placebo), 22 mg/kg (1X), 66mg/kg (3X), and 110 mg/kg (5X) for 12 weeks, and at 22 mg/kg twice a day for 12 weeks. The most common clinical findings included epiphora, salivation, vomiting and diarrhea among all the dose groups. Three dogs had decreased activity (1 in each from the 22 mg/kg twice a day, 22 mg/kg three times a day, and the 66mg/kg three times a day groups). These observations were mild and sporadic.

There were increases in alanine aminotransferase (ALT) in the 110 mg/kg three times a day group and in the 22 mg/kg twice a day group that increased in a dose-dependent pattern. There was an increase in sorbitol dehydrogenase (SDH) in the 110 mg/kg three times a day group compared to the controls. These changes were minimal and the values remained within expected historical control ranges. There were several decreases in total protein (in the 110 mg/kg three times a day group) and/or globulin (in the 22, 66, and 110 mg/kg three times a day groups) compared to the controls. These changes resulted in occasional increases in albumin/globulin ratios. Although a drug effect cannot be ruled out, these changes were not clinically relevant.

A mild prolongation in prothrombin time (PT) was observed in the 22 mg/kg three times a day group. This was not considered clinically relevant due to the small change that remained within the reference ranges.

One dog in the 110 mg/kg three times a day group had moderate amounts of bilirubinuria at the Week 8 and Week 12 samplings. No clinical significance was noted.

Cephalexin was not present in any Day 1 samples prior to dosing or in any control animals. After dosing, cephalexin was well absorbed into systemic circulation of the treated dogs. Within gender and dosage level, Week 8 mean trough concentrations were generally higher than the Week 4 and 12 mean trough concentrations (between a 0.9 and 3.6-fold difference). The geometric mean plasma cephalexin trough concentration following three times daily administration of the 110 mg/kg dose was 11.2 µg/mL compared to 2.6 µg/mL and 8.7 µg/mL following 22 mg/kg and 66 mg/kg, respectively at Week 12. Geometric mean plasma cephalexin trough concentrations following administration of 22 mg/kg twice daily were 0.7, 1.3, and 1.0 µg/mL at Weeks 4, 8, and 12, respectively.

STORAGE INFORMATION: Store at 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F).

HOW SUPPLIED: RILEXINE® (cephalexin tablets) Chewable Tablets are supplied in 150 mg, 300 mg, and 600mg tablets packaged in bottles of 100 tablets.

Approved by FDA under NADA # 141-326

Manufactured by Virbac AH, Inc.
Fort Worth, TX 76161 USA

150 mg 07620 302054-06, 300 mg 07630 302055-06, 600 mg 07640 302056-06; Rev. date 01/2024

¹Birchard SJ and Sherding RG. Saunders Manual of Small Animal Practice, 2nd edition. W.B. Saunders Co. 2000; p. 166.

²Adams HR. *Veterinary Pharmacology and Therapeutics*, 8th edition, 2001, p. 825.

© 2024 Virbac Corporation. All rights reserved.
RILEXINE is a registered trademark of the Virbac Group of Companies.